Kimberly Manhard
Kimberly J Manhard is a biopharmaceutical executive with more than 25 years of experience in research and development. She is currently working as an independent biotech consultant. Ms. Manhard has also served as the Executive Vice President of Drug Development for Heron Therapeutics, Inc. (Heron) and as a board director for Heron. Additionally, Ms. Manhard serves as a board director of Toragen, Inc. and of InhibRx, Inc., which are focused on the research and development of new treatments for cancer, and Shoreline Biosciences, Inc, which is developing induced pluripotent stem cell therapies. Prior to joining Heron, Ms. Manhard held senior executive roles at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC, and at Exelixis, Inc. and previously worked in regulatory positions at Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer, and Bristol-Myers Squibb Company supporting development and commercialization of anticancer and antiviral products. Ms. Manhard began her industry career in clinical research with Eli Lilly and Company.
Ms. Manhard resides in the San Diego, California area and is a member of the board of trustees for the Fleet Science Center there.
Education
➤ BA in French, from the University of Florida
➤ BS in Zoology, from the University of Florida